GPGI Reports Second Quarter 2026 Results

GPGI reported Q2 pro forma adjusted net sales of $473.2M (-4% YoY) and pro forma adjusted EBITDA of $113.9M (-13% YoY), with the adjusted EBITDA margin down 230 bps to 24.1%; GAAP net income was $50.3M. The company reiterated full-year 2026 guidance: pro forma adjusted net sales of $1.95B–$2.10B (flat at midpoint) and pro forma adjusted EBITDA of $550M–$610M (+7% at midpoint), targeting $275M–$325M of pro forma adjusted free cash flow. Management cited record strength at CompoSecure and transient headwinds at Husky, and highlighted ongoing platform progress under the Resolute Operating System.

Analysis

The market should separate the cleaner, higher-multiple CompoSecure asset from the industrial/cyclical Husky exposure. CMPOV is the best relative winner because its earnings quality is better, its end markets are less capex-sensitive, and every quarter of “record” operating performance increases the odds it deserves a standalone premium rather than being buried inside a holding-company structure. By contrast, GPGI remains a complexity discount story: high leverage, heavy non-cash accounting noise, and a conglomerate wrapper make it harder for investors to underwrite the true run-rate cash earnings.

Second-order, the weaker Husky tape matters more for customers and peers than the press release admits. If order timing is slipping, that can cascade into tooling, automation, and resin-adjacent suppliers, while also pressuring packaging-capex names that rely on a healthy replacement cycle. The key offset is aftermarket service, which should cushion downside, so this is more a margin/revenue deferral story than a demand collapse.

The catalyst path is 1-3 months of order-book and margin checks, not this print. The 6-18 month story is deleveraging toward ~3x and whether management can prove that ROS is raising conversion rather than simply reclassifying costs. The main falsifier is a visible re-acceleration in Husky bookings or a sharp step-up in CMPOV growth that makes the holding-company discount less relevant.

Key Decisions for Investors

• Long CMPOV / short GPGI for 1-3 months: express the cleaner earnings quality vs. conglomerate-discount gap; target outperformance if CMPOV continues to print high-margin growth while GPGI stays flat-to-down on EBITDA.
• Avoid chasing GPGI on any post-print bounce; use rallies to fade until there is proof of sequential margin expansion and tangible leverage reduction, not just reiterated guidance.
• Watch for a pair trade unwind trigger: if GPGI reports 3Q book-to-bill improvement or raises full-year free cash flow, cover the short—this would imply the Husky headwind is timing, not structural.
• If CMPOV pulls back with the broader market, accumulate on weakness rather than strength; the thesis needs 2-3 quarters of execution, but the downside is better contained than in the parent.